Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tarsus Pharmaceuticals (NASDAQ:TARS) from a hold rating to a buy rating in a research report released on Saturday morning.

Several other research analysts have also recently commented on TARS. HC Wainwright boosted their price target on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. Zacks Research upgraded Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. The Goldman Sachs Group reiterated a “neutral” rating and set a $51.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday. Finally, Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $69.83.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $72.79 on Friday. The firm has a fifty day simple moving average of $63.05 and a 200-day simple moving average of $51.41. The company has a market capitalization of $3.09 billion, a PE ratio of -36.03 and a beta of 0.82. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $76.81. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. Equities research analysts anticipate that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 27,116 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the transaction, the director owned 143,332 shares of the company’s stock, valued at $8,169,924. The trade was a 15.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. The trade was a 0.73% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Driehaus Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals during the first quarter worth about $36,876,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Tarsus Pharmaceuticals during the first quarter valued at approximately $26,199,000. Norges Bank bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $19,095,000. MPM Bioimpact LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $13,834,000. Finally, TimesSquare Capital Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $15,898,000. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.